Option chain shows key data for NeuroSense Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for NeuroSense Therapeutics.

NeuroSense Therapeutics (NASDAQ:NRSN) Stock, Option Chain

NeuroSense Therapeutics

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

NRSN

News

Health Care

Market-Moving Exclusives

Exclusives

General

NeuroSense Therapeutics schedules an FDA Type C meeting on Nov. 6 to finalize its Phase 3 trial design for PrimeC, a potential ALS treatment.

EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission

Screenshot 2024-10-17 at 10.10.15 PM

Biotech

NeuroSense Advances Plans For Early Commercialization Of Potentially Groundbreaking ALS Treatment In Canada, Targeting A $100M+ Market

NeuroSense Therapeutics is in advanced talks with major pharmaceutical companies for a strategic partnership to develop and commercialize its ALS drug, PrimeC. The company expects to receive terms by Q4 2024, but final agreements are not yet assured.

EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug

NeuroSense Therapeutics Ltd. - Ordinary Shares

NeuroSense Therapeutics Ltd

Press Releases

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

Offerings

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

Earnings

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

Small Cap

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

Alliance Global Partners

Comments

NeuroSense Therapeutics

NeuroSense Therapeutics (NRSN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga